Stock ONC ONCIMMUNE HOLDINGS PLC
Add to a list
To use this feature you must be a member
Log inSign up

Company Oncimmune Holdings plc

Equities

ONC

GB00BYQ94H38

Pharmaceuticals

Market Closed - London S.E.
Other stock markets
 11:35:16 2024-04-18 am EDT 		5-day change 1st Jan Change
29.1 GBX +10.23% Intraday chart for Oncimmune Holdings plc +38.57% +15.48%
Feb. 29 Oncimmune Holdings plc Provides Earnings Guidance for the Year 2024 CI
Feb. 29 Oncimmune Holdings plc Reports Earnings Results for the Full Year Ended August 31, 2023 CI

Business Summary

Oncimmune Holdings plc is a United Kingdom-based immunodiagnostics developer, primarily focused on the growing fields of immuno-oncology, autoimmune disease and infectious diseases. The Company's principal activity is the development and commercialization of technologies that enable cancer diagnosis. Its service offerings include ImmunoINSIGHTS. The ImmunoINSIGHTS service business leverages its technology platform and methodologies across multiple diseases, to offer life-science organizations actionable insights for therapies across the development and product lifecycle. Its immune-profiling technology helps the Company in identifying trial participants and patients into clinically relevant subgroups, which enables the development of targeted treatments. The Company's subsidiaries include Oncimmune Americas LLC, Oncimmune Germany GmbH, and Oncimmune LLC, among others.

Number of employees: 52

Sales per Business

GBP in Million2022Weight2023Weight Delta
ImmunoINSIGHTS
100.0 %
2 60.8 % 1 100.0 % -37.47%

Sales per region

GBP in Million2022Weight2023Weight Delta
Rest of the World
93.1 %
1 21.4 % 1 93.1 % +65.64%
Europe
6.9 %
1 19.8 % 0 6.9 % -86.67%

Managers

Managers TitleAgeSince
Martin Gouldstone CEO
 Chief Executive Officer 57 23-07-31
Martin Hudson DFI
 Director of Finance/CFO - 23-09-03
James R. Jett CTO
 Chief Tech/Sci/R&D Officer - 15-10-31
Tariq Sethi CTO
 Chief Tech/Sci/R&D Officer - 19-09-30
Ron Kirschner COO
 Chief Operating Officer - 20-04-19
Cléa Rosenfeld IRC
 Investor Relations Contact - 19-06-30
Matthew Luttrell PRN
 Corporate Officer/Principal - 19-09-30
Cameron Barnard PRN
 Corporate Officer/Principal - 21-07-31

Members of the board

Members of the board TitleAgeSince
John Goold BRD
 Director/Board Member 52 23-01-12
Timothy Bunting BRD
 Director/Board Member 61 15-10-08
Ron Kirschner COO
 Chief Operating Officer - 20-04-19
Martin Gouldstone CEO
 Chief Executive Officer 57 23-07-31
Sally Christina Waterman BRD
 Director/Board Member - 23-10-11
Alistair Macdonald CHM
 Chairman 54 22-07-07

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 74,142,147 52,785,507 ( 71.20 %) 0 71.20 %

Shareholders

NameEquities%Valuation
Balderton Capital (UK) LLP
9.189 %
6,813,196 9.189 % 2 M p
Richard Sharp
6.597 %
4,891,444 6.597 % 1 M p
Timothy Bunting
6.551 %
4,856,717 6.551 % 1 M p
Gene Group Holdings Ltd.
4.445 %
3,295,659 4.445 % 882 610 p
Hargreaves Lansdown Asset Management Ltd.
4.232 %
3,137,967 4.232 % 840 379 p
Chelverton Asset Management Ltd.
4.056 %
3,007,500 4.056 % 805 439 p
SpreadEx Ltd.
2.486 %
1,843,032 2.486 % 493 582 p
Unicorn Asset Management Ltd.
1.565 %
1,160,000 1.565 % 310 660 p
John Goold
1.551 %
1,150,000 1.551 % 307 982 p
Maven Capital Partners UK LLP
0.4869 %
360,985 0.4869 % 96 675 p

Company contact information

Oncimmune Holdings Plc

D6 Building 1 Thane Road

NG90 6BH, Nottinghamshire

+

http://www.oncimmune.co.uk
address Oncimmune Holdings plc(ONC)

Sector

Healthcare
Pharmaceuticals & Medical Research
Pharmaceuticals
Pharmaceuticals
Specialty & Advanced Pharmaceuticals

Sales per Business

Sales per region

Annual profits - Rate of surprise

Company calendar

Sector Specialty & Advanced Pharmaceuticals

1st Jan change Capi.
ONCIMMUNE HOLDINGS PLC Stock Oncimmune Holdings plc
+15.48% 24.36M
KYOWA KIRIN CO. LTD. Stock Kyowa Kirin Co. Ltd.
+11.18% 9.08B
SK BIOPHARMACEUTICALS CO., LTD. Stock SK Biopharmaceuticals Co., Ltd.
-15.94% 4.57B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD. Stock Shenyang Xingqi Pharmaceutical Co.,Ltd.
+18.47% 3.9B
YUHAN CORPORATION Stock Yuhan Corporation
+1.89% 3.69B
INDIVIOR PLC Stock Indivior PLC
+28.61% 2.62B
CHANGCHUN BCHT BIOTECHNOLOGY CO. Stock Changchun BCHT Biotechnology Co.
-24.63% 2.34B
BETTA PHARMACEUTICALS CO., LTD. Stock Betta Pharmaceuticals Co., Ltd.
-29.37% 2.14B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD. Stock Shanghai Shyndec Pharmaceutical Co., Ltd.
+2.55% 1.84B
VELOXIS PHARMACEUTICALS A/S Stock Veloxis Pharmaceuticals A/S
-0.50% 1.64B
Specialty & Advanced Pharmaceuticals
  1. Stock Market
  2. Equities
  3. ONC Stock
  4. Company Oncimmune Holdings plc